PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION

Show other versions (1)

Disadvantages of vitamin K antagonist warfarin and the benefits of new anticoagulants, including dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors that influence the choice of dabigatran dose in different individuals are discussed. Dabigatran...

Full description

Bibliographic Details
Main Authors:	E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko
Format:	Article
Language:	English
Published:	Столичная издательская компания 2015-09-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	atrial fibrillation stroke prevention new oral anticoagulants dabigatran etexilate
Online Access:	https://www.rpcardio.online/jour/article/view/232

Similar Items

Dabigatran etexilate in patients with nonvalvular atrial fibrillation: benefits of application in certain clinical situations
by: E. I. Baranova, et al.
Published: (2019-11-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Monitoring the use of dabigatran etexilate for stroke prevention: compliance with renal function guidelines
by: Alesha J. Smith, et al.
Published: (2020-01-01)

PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
by: E. D. Kosmacheva, et al.
Published: (2015-09-01)

Dabigatran etexilate: a direct thrombin inhibitor
by: M. Dugnani
Published: (2013-05-01)

Budget impact analysis resulting from the use of dabigatran etexilate in preventing stroke in patients with non-valvular atrial fibrillation in Italy
by: Francesco Mennini, et al.
Published: (2012-09-01)

New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
by: E. I. Baranova
Published: (2018-11-01)

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
by: Josef Finsterer, et al.
Published: (2012-02-01)

Dabigatran etexilate for nonvalvular atrial fibrillation in real practice and promises for its use to prevent stroke
by: A.V. Fonyakin
Published: (2014-06-01)

Dabigatran etexilate in the prevention of cardioembolic complications in patients with non-valvular atrial fibrillation
by: IS Yavelov
Published: (2014-12-01)

The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation
by: A. V. Fonyakin
Published: (2015-06-01)

Exposure Response Supports Therapeutic Drug Monitoring for Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2019-07-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
by: Bryan H. Simpson, et al.
Published: (2018-10-01)

Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT)
by: Uğur Önsel Türk, et al.
Published: (2016-05-01)

Design and synthesis of dabigatran etexilate derivatives with inhibiting thrombin activity for hepatocellular carcinoma treatment
by: Zhuo-song Xie, et al.
Published: (2024-01-01)

The Discovery of Dabigatran Etexilate
by: Joanne evan Ryn, et al.
Published: (2013-02-01)

Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the RE‐CIRCUIT trial
by: Yukihiko Yoshida, et al.
Published: (2018-04-01)

DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER
by: I. S. Yavelov
Published: (2016-01-01)

Recovery of Visual Function after Administration of Dabigatran Etexilate
by: Carl-Ludwig Schönfeld, et al.
Published: (2014-08-01)

Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI
by: A. D. Erlich
Published: (2019-04-01)

Population pharmacokinetic analysis for dabigatran etexilate in Chinese patients with non-valvular atrial fibrillation
by: Ya-ou Liu, et al.
Published: (2022-10-01)

Investigation of Solid-State Hydrate-Anhydrous Phase Transformations of Dabigatran Etexilate Hemi-Edisylate
by: Jin Feng, et al.
Published: (2023-03-01)

Clinical performance of the atrial fibrillation in the Russian population depending on the antithrombotic therapy: findings from the GLORIA-AF registry phase 2
by: E. V. Shlyakhto, et al.
Published: (2020-12-01)

Reliability and safety of long-term dabigatran use in patients with atrial fibrillation
by: E. V. Serdechnaya, et al.
Published: (2013-04-01)

Bioequivalence and pharmacodynamics of a generic dabigatran etexilate capsule in healthy Chinese subjects under fasting and fed conditions
by: Xin Li, et al.
Published: (2020-04-01)

Post-marketing surveillance on the long-term use of dabigatran in Japanese patients with nonvalvular atrial fibrillation: Preliminary report of the J-dabigatran surveillance
by: Hiroshi Inoue, et al.
Published: (2016-04-01)

Spinal subarachnoid and subdural hematoma presenting as a Brown-Séquard-like myelopathy following minor trauma in a patient on dabigatran etexilate
by: Allen R. Wolfe, MD, MPH, et al.
Published: (2017-06-01)

Type of anaesthesia and the safety and efficacy of thromboprophylaxis with enoxaparin or dabigatran etexilate in major orthopaedic surgery: pooled analysis of three randomized controlled trials
by: Rosencher Nadia, et al.
Published: (2012-06-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

The preoperative management of dabigatran and its specific antidote idarucizumab in patients with nonvalvular atrial fibrillation: Case reports
by: Tomić Milan
Published: (2020-01-01)

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Dabigatran etexilate, a novel oral direct thrombin inhibitor, for preventing thromboembolic events after knee replacement arthroplasty
by: Moghtadaee M, et al.
Published: (2012-02-01)

HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION
by: S. V. Moiseev
Published: (2015-12-01)

Relationship between plasma dabigatran concentration and activated partial thromboplastin time in Japanese patients with non-valvular atrial fibrillation
by: Daiki Shimomura, et al.
Published: (2015-08-01)

The Complementary Effects of Dabigatran Etexilate and Exercise Training on the Development and Stability of the Atherosclerotic Lesions in Diabetic ApoE Knockout Mice
by: Nikolaos PE Kadoglou, et al.
Published: (2023-10-01)

Comparison of Clinical and Biochemical Parameters in Atrial Fibrillation Patients Using Dabigatran and Rivoraxaban and Their Relationship with Complications
by: İrfan Aydın, et al.
Published: (2020-03-01)

Characteristics of Japanese Patients with Nonvalvular Atrial Fibrillation on Anticoagulant Treatment: A Descriptive Analysis of J-dabigatran Surveillance and JAPAF Study
by: Yukihiro Koretsune, et al.
Published: (2019-02-01)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
by: Sergio J. Dubner, et al.
Published: (2020-10-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)